ACYQ vs PAYH: Dividend Yield & Total Return
ACYQ and PAYH both write options for income. Net assets: $100m on Oct 20, 2026 for FT Vest Autocallable Barrier & High Income ETF, and $26m on Jul 31, 2026 for TrueShares S&P Autocallable High Income ETF.
PAYH costs 0.01 points a year less.
| ACYQ | PAYH | |
|---|---|---|
| Expense ratio | 0.75% | 0.74% |
| Net assets, ACYQ as of Oct 20, 2026 and PAYH as of Jul 31, 2026 | $100m | $26m |
| Holdings in common | 0% | |
| Price change | rose 2.6% (since Jun 24, 2026) | fell 0.8% (since Dec 30, 2025) |
Holdings in common uses holdings dated Jul 31, 2026 and Oct 19, 2026.
Not measured
ACYQ since launch: paid 3.8%, price +2.6%, total +6.4%, not measured against a benchmark. Figures to Oct 20, 2026.
ACYQ
+6.4%
3.8% of it arrived as cash
Total return, distributions reinvested
Not measured
ACYQ since launch: paid 3.8%, price +2.6%, total +6.4%, not measured against a benchmark. Figures to Oct 20, 2026.
ACYQ
+6.4%
3.8% of it arrived as cash. Total return, distributions reinvested. ACYQ since launch: paid 3.8%, price +2.6%, total +6.4%, not measured against a benchmark. Figures to Oct 20, 2026.
Figures to Oct 20, 2026.
Not measured
PAYH since launch: paid 12.1%, price −0.8%, total +12.4%, not measured against a benchmark. Figures to Oct 20, 2026.
PAYH
+12.4%
12.1% of it arrived as cash
Total return, distributions reinvested
Not measured
PAYH since launch: paid 12.1%, price −0.8%, total +12.4%, not measured against a benchmark. Figures to Oct 20, 2026.
PAYH
+12.4%
12.1% as cash
12.1% of it arrived as cash. Both charts share one scale, with zero at the line. PAYH since launch: paid 12.1%, price −0.8%, total +12.4%, not measured against a benchmark. Figures to Oct 20, 2026.
Figures to Oct 20, 2026.
What they hold in common
By the books each fund has filed, ACYQ and PAYH hold 0% of their money in the same securities at the same weight. Holdings dated Jul 31, 2026 and Oct 19, 2026.
half
0% in common
Performance, window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | ACYQ | PAYH | ACYQ | PAYH | ACYQ | PAYH |
| 3 months | +5.5% | +4.4% | 3.8% | 4.2% | not measured | not measured |
| 6 months | – | +7.5% | – | 8.4% | – | not measured |
| Since launch Not the same days: ACYQ Jun 2026 · PAYH Dec 2025 | +6.4% | +12.4% | 3.8% | 12.1% | not measured | not measured |
Source: ETFIQ. – means no data for this window, usually because the fund is younger than it. Open this comparison in the app →
On the same fields
As of Oct 20, 2026. Source: ETFIQ. Cash paid is what the fund distributed over the window, as a share of its price at the start. Payout rate is its latest payment, annualized, over today’s price.
About ACYQ
Over the period from its first trade on Jun 24, 2026 to Oct 20, 2026, ACYQ paid 3.8% of its starting value in cash distributions while its price rose 2.6%. With every distribution reinvested, the fund returned +6.4%. At its price on Oct 20, 2026 the latest distribution annualizes to 23.0%, paid periodically.
About PAYH
Over the period from its first trade on Dec 30, 2025 to Oct 20, 2026, PAYH paid 12.1% of its starting value in cash distributions while its price fell 0.8%. With every distribution reinvested, the fund returned +12.4%. At its price on Oct 20, 2026 the latest distribution annualizes to 16.9%, paid monthly.
Questions people ask
ETFIQ links to the documents behind every figure; a link is not an endorsement. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every figure is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, ACYQ against PAYH, data as of Oct 20, 2026. https://etfiq.com/compare/income/acyq-vs-payh
ETFIQ. (Oct 20, 2026). ACYQ against PAYH. Retrieved from https://etfiq.com/compare/income/acyq-vs-payh
[ACYQ against PAYH (ETFIQ, Oct 20, 2026)](https://etfiq.com/compare/income/acyq-vs-payh)
Free to use with attribution for figures ETFIQ computes; issuer data stays under its owner's terms.